Insiders at Madrigal (NASDAQ: MDGL) detail recent stock sales

Rhea-AI Filing Summary

Madrigal Pharmaceuticals insider files a Form 144 notice for a planned stock sale. The filing covers a proposed sale of 2238 shares of Madrigal common stock through Morgan Stanley Smith Barney LLC on or about 01/20/2026, with an aggregate market value listed as 1122759.84 and 22711420 shares of common stock outstanding. The shares to be sold were acquired on 01/16/2026 via a restricted stock unit grant from the issuer, vesting the same day.

The notice also lists recent Rule 10b5-1 plan sales in the past three months. For Rebecca A. Taub, there were two sales of 18650 shares each on 12/10/2025 and 01/09/2026, with gross proceeds of 10297573.26 and 9749391.94. For Paul A. Friedman, there were two sales of 24800 shares each on the same dates, with gross proceeds of 13694158.24 and 12963304.72.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza, 8th Floor New York NY 10004	2238	1122759.84	22711420	01/20/2026	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/16/2026	Restricted Stock Unit Grant	Issuer			2238	01/16/2026	Vesting of Restricted Stock Units

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for REBECCA A TAUB c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	01/09/2026	18650	9749391.94
10b5-1 Sales for REBECCA A TAUB c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	12/10/2025	18650	10297573.26
10b5-1 Sales for PAUL A FRIEDMAN c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	01/09/2026	24800	12963304.72
10b5-1 Sales for PAUL A FRIEDMAN c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	12/10/2025	24800	13694158.24

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Madrigal Pharmaceuticals (MDGL) Form 144 report?

The Form 144 reports a planned sale of Madrigal Pharmaceuticals common stock by an insider, including details on the number of shares, broker, market value, and how the shares were acquired.

How many MDGL shares are planned for sale under this Form 144?

The notice covers a proposed sale of 2238 shares of Madrigal Pharmaceuticals common stock, to be sold through Morgan Stanley Smith Barney LLC.

When were the MDGL shares in this Form 144 acquired and how?

The 2238 shares were acquired on 01/16/2026 through a restricted stock unit grant from Madrigal Pharmaceuticals, with vesting of the restricted stock units serving as the form of payment.

What recent 10b5-1 stock sales by MDGL insiders are disclosed?

The filing lists Rule 10b5-1 sales in the past three months: Rebecca A. Taub sold 18650 shares on 12/10/2025 and 18650 shares on 01/09/2026, and Paul A. Friedman sold 24800 shares on 12/10/2025 and 24800 shares on 01/09/2026, with gross proceeds shown for each transaction.

What is the market value and share count context for this MDGL Form 144?

The planned sale of 2238 shares is shown with an aggregate market value of 1122759.84, and the filing notes that 22711420 shares of Madrigal Pharmaceuticals common stock are outstanding.

Which exchange is referenced for the MDGL shares in this filing?

The Form 144 identifies the Nasdaq Stock Market as the exchange for Madrigal Pharmaceuticals common stock related to this planned sale.

Which broker is handling the planned MDGL stock sale?

Morgan Stanley Smith Barney LLC Executive Financial Services, based at 1 New York Plaza, 8th Floor, New York, NY 10004, is listed as the broker for the planned 2238-share sale.